Ten23 health acquires first company shortly after launch

Swissfillon will join ten23 to enhance the companies’ integrated offering of drug product development services and fill-finish manufacturing to their combined group of customers. Swissfillon is a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices. The company, which was founded in 2013, employs over 50 people and is a specialized player in the global CDMO (contract development and manufacturing organization) market. Its operations have been approved by Swissmedic for the European market since 2018 and by the FDA for the US market since 2019. The company currently supports various clinical and early commercial customer programs.

Swissfillon manufactures sterile dosage forms (usually a syringe, cartridge or vial) which allow a drug substance to be administered to a patient to meet the increasing market demand for complex products and patient centric application forms. Biologics are sensitive to temperature and manufacturing stresses and are often developed for applications such as intraocular or subcutaneous injection, requiring specific expertise in both development and manufacturing.

The combined business of ten23 health and swissfillon will provide an integrated offering for sterile drug product development and manufacturing of biologics, challenging molecules and dosage forms. Swissfillon will continue to operate under its brand, which stands for first-class Swiss quality and excellent know-how. Hanns-Christian Mahler will serve as CEO of the combined entities under the ten23 health umbrella. Daniel Kehl, founder of swissfillon, will remain with the business in a key leadership role and will help to lead ten23’s new infrastructure engineering projects that are of great strategic importance for the further development of the combined offering.

Hanns-Christian Mahler, CEO of ten23 health, commented: «Sterile fill and finish services are expected to experience significant growth over the coming years. The rising demand is driven by expanded drug development pipelines, incorporating more complex, large-molecule products and therapies that require specific expertise for both development and sterile production. » He added: «This is precisely why we expect ten23 health´s services, now including swissfillon, to be in great demand. At ten23 health, we are very pleased that we can now offer this sought-after know-how to biotech startups and pharmaceutical companies from one single source.» Both parties have agreed not to disclose the purchase price.

(Press release / SK)